Search

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

Highlights from the SWG

During 2023, the SWG:

Held a joint scientific meeting with the SWG on Myelodysplastic Syndromes and the SWG on Acute Myeloid Leukemia
Commenced work on guidelines for young MPN patients
Delivered a presentation for the American Society of Hematology (ASH) on the database…

Read more

The invisible burden of the pandemic

Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.

Read more

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.

Read more

SWG Educational Activities

The SWG's recent educational activities have included:

Meetings with the SWG on Myelodysplastic Syndromes and the SWG on Acute Myeloid Leukemia
An EHA-SWG Scientific Meeting on 'MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms'
An oral presentation for the American Society of Hematology (ASH)…

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more